Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone needs some shares? Buddy of mine has close to 1m he wants to dump.
Business Summary
Gene Biotherapeutics Inc. is a clinical-stage biotechnology company, which is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.
Come on CRXM...let's go!
I just looked back at this valuation comparison that management gave you and took a glance at TNYA's market cap. Was very surprised to see it was at $372m.
I know this management is prone to exaggeration or possibly even misguiding shareholders but even if they were off by a factor of 10, that would leave us with a $37M market cap and close to 45 cents per share. I would be ecstatic with that, hell, I would be ecstatic with half that.
I don't know if considering the companies current status if a SEC filing would need to be done or not.
Was the offer to buy real? I have people who want to sell.
$CRXM
— OTC Updates (@OtcUpdates) June 16, 2023
💰0.0001
Expert Market, AS: 200M, OS: 64M
Transfer Agent(s) Removed:
🔴Computershare U.S.(Good Standing, Public)...
Full Details: https://t.co/F7MWRMUB32
I remember Sabby was here…..
Hey @SECGov
— 🍏DvG #ItsAMCforMe🍿🎥🍿DuckTheNoise! Hot Pockets! (@_DavidVsGoliath) June 13, 2023
Carolyn Welshhans@SECEnfDirector,
how about you disclose definitively which 10+ securities were
ILLEGALLY Naked Shorted?
You know, like be transparent! https://t.co/ZS9hpa5DwW pic.twitter.com/pTrKww6hOD
I agree volume was low but cosidering the illegal naked shorting aspect, official volume may not reflect reality.
I did email the SEC. If they respond, I'll let the board know. So far no response from CR.
When it was trading, there really wasn't enough volume to indicate shorting. With that said, it shouldn't have prevented keeping up with filings.
I always thought CRXM would have been a good reverse merge candidate for Norstrom. (good exit strategy for principals).
Glad to see SEC go after Sabby...
I sent the SEC PR about Sabby to CR. Folks might want to reach out to the SEC and inquire if CRXM was one of Sabbys targets.
Very interesting. Even if they did naked short us, it is still incumbent upon the company to keep all filings up to date, which they did not.
Sniff, Sniff, Sniff……Sabby was here?
https://www.sec.gov/news/press-release/2023-107
I remember sometime ago Sabby was playing nice here and trying to tell everyone that he is kind of financing the company. Maybe shorted the company to death. CR should check this out.
https://www.stl.news/sec-charges-sabby-management-llc-and-hal-d-mintz/619825
CRXM might want to get funding before the overall economy is in really bad shape. This downturn might last for years! I guess these people incharge had no clue had to get what was needed prior to doing absolutely nothing with this Ticker???
CRXM??
Someone needs to pony up for a subscription. I mean geez, the guy is offering to possibly buy a ton of shares.
Free Users can't send PM. Only Friday 4-5pm I believe is free
Click on the Altitrade Partners profile name and it will take you to a page where you can send a private message.
Hey. I was told you are interested in shares. I don't know how to privately reach you
Will do, thanks...
Try these:
creinhard@genebiotherapeutics.com
info@genebiotherapeutics.com
I used them recently. Did not kick back. No response though. I think I relayed to him that angionetics address wasn't working.
It worked back on 15 Dec as I received a response from him.
On Thursday, December 15, 2022, 07:31:10 PM GMT+3, Christopher Reinhard <creinhard@angionetics.com> wrote:
Christopher Reinhard <creinhard@angionetics.com>
"I am still hopeful here but refuse to believe anything until I see it in official form."
Could not agree more. I think CR needs to put some type of update out. I just don't see why a legit CEO would leave investors hanging this long. A pending partnership/uplisting or buyout would be the exception.
What emails addresses are you using?
Agree....Shareholders Need Action.....Financials Up To Date.....Funding For Generx Phase 3.....Start Of Phase 3......A Clear Path And Game Plan Moving Forward.....I Believe It Will Happen
Agreed...and my e-mails come back undeliverable now.
NEVER A GOOD SIGN.
Bentleyt, while I want to share your optimism, I would caution you about getting too far over your skis here. If I remember correctly, you were told a few things before the company went into the abyss almost two years ago. I am still hopeful here but refuse to believe anything until I see it in official form. Fool me once....
I Was Told That Generx Has A 10 Year Lead Against Any Competing Drug/Medicine.....This Was Said To Me About A Year Ago From The CRXM CEO.....So It Is Very Valuable
I have someone for you. I can not Private Message you their contact until happy hour though.
Given Altitrade Partners deep research I hope they/you are right. My personal preference, as well as my families, would be to see progress being made and a private buyout. This would be so much less complicated for everyone.
I wonder if Altitrade Partners has done a valuation recently. It has been a while. Has the market for Generx changed? Any other therapies catching up?
I'd also like to understand what the situation with Nostrum is at this time. Why did they take such a large interest in CRXM only to have Generx sit on a shelf?
Altitrade's Offer Equates To Better Days Ahead!
Given that we have no idea what is happening, definitely! Very generous
That’s probably too generous an offer.
Reasonable offer (I’d take it without hesitation if I still had anything close to that). I will pass it along by the end of the week and refer them here if they want to accept.
That's a legit offer!
I was thinking more along these lines
Up to 100,000 shares - $0.05 each
Between 100,000 and 499,999 shares - $0.04 each
Over 500,000 shares $ - 0.03 each
I will only purchase shares up to 9.9% of the total shares outstanding.
I am currently at about 6.2%. I am not looking to obtain affiliate status, which is 10% or greater
I have 2 people with total of 5.5m shares combined. I can pass on the offer as they’re anxious to sell. What is the offer? I don’t think they’ll bother selling for current market price
Heck of a way to lower your cost average in case we open back up on a higher exchange based on momentum from partnerships and trial progress. Better yet a buyout.
Hell @ current value of .0001 I'll even buy them!...At this price, one could even make a few bucks on a shell takeover!
Strong conviction there Altitrade Partners.
If you know of anyone who wants to sell shares in a private transction, I would be willing to act as the buyer. They would need to have their shares issued in certificate form and then sign the shares over to me via a stock power.
I assume Christopher J. Jemapete is you. Hope you are right on this one. Some of my acquaintances are still heavily invested in this.
I recall you laying that out for folks in your blogs etc. I don't disagree it may turn out to be a benefit.
Still, CRXM is a public company with shareholders who purchased shares on the open market based on public documents etc.
It wouldn't hurt for CRXM to put out an update, even if it is just as a banner on the website for those of us following along. I too trust CR to move things along. Considering the silence, lack of filings and reported difficulty reaching CR, it would be a help to hear something.
The biggest risk i see is that Reinhart is the "magic" of this biz and if anything happens to him (or his willingness and drive), this will just fade into history.
We have said all along that we look at our investment in Gene Biotherapeutics as if we were investing in a private company. Since we plan on holding our shares for at least another 3-5 years, we don't care about there not being a market for the stock. Why should we care about a lack of liquidity when we have no intention of selling any of our shares for a long time.
Actually, we see this as an advantage, in the sense that it forces us to hang on to our shares, and not be influenced by prevailing market forces. If we were not distracted and didn't get caught up in all of the noise surrounding CELH, we would still likely have the 568,250 shares that we held in our Roth IRA account at an average price of $0.22.
Those shares today would be worth over $74 million
https://i.postimg.cc/52xVycQW/Fidelity-CELH-Position-2-28-2015.jpg
We have confidence that Chris Reinhard will get a deal done to fund a successful Phase 3 clinical trial. The filings are secondary to us. While it may be difficult now, we believe that things will ultimately improve.
Don't underestimate the importance of patience when investing in micro-caps.
He bought it between 3-6c. Let’s say average of 4c, that’s still 160k. Worth fighting for
As I recall he is in at a very good average price. I doubt he is very concerned about his investment. I could be wrong. No one likes losing money. Especially considering the company clearly lead investors to believe they were getting current etc.
Christopher J. Jemapete filed Schedule 13G/A on 02/2023.
I’m surprised no legal action yet. He has 4m shares/ 65m
On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.
Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1
Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/
Taxus Cardium Announces Name Change To Gene Biotherapeutics
January 10, 2018 PR-M01-18-NI-021
SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc.
The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs. Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.
Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities. Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged. As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.
Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.
Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.
Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates. To learn more about Angionetics visit www.angionetics.com.
As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications. Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes. Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.
As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |